ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
98,075.01
1.22%
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs Yen
157.195
-0.11%
Brent Oil
76.495
0.84%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) ニュース

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CGEM
日付受信時刻ニュースソース見出しコード企業名
2024/12/2107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/12/2107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/12/2107 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/12/1707 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/11/1507 : 05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
2024/11/1500 : 01GlobeNewswire Inc.Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0904 : 17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0807 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0721 : 18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0721 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0721 : 00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0521 : 00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
2024/11/0421 : 00GlobeNewswire Inc.Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
2024/10/2304 : 24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
2024/10/1620 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
2024/10/1620 : 00GlobeNewswire Inc.Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
2024/09/1720 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
2024/09/1720 : 00GlobeNewswire Inc.Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
2024/09/1620 : 00GlobeNewswire Inc.Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
2024/09/1417 : 15GlobeNewswire Inc.Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024NASDAQ:CGEMCullinan Therapeutics Inc
2024/09/1006 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/09/0605 : 27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
2024/08/2821 : 00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
2024/08/0820 : 00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0513 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0506 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0321 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
2024/06/0120 : 00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/2421 : 00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
2024/05/2406 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CGEM

最近閲覧した銘柄

CCOM
US30
US 30
NYSE
XOM
Exxon Mobil
NYSE
MRK
Merck
AMEX
XLF
Financial Select Sector
AMEX
SPY
SPDR S&P 500
AMEX
XLE
Energy Select Sector SPDR
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
NASDAQ
TSLA
Tesla
NYSE
KO
Coca Cola
AMEX
XLV
Health Care Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
BASFY
BASF (QX)
CCOM
SILVER
SILVER
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有